Close Menu

Natera

PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.

Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.

The molecular diagnostics firm grew year-over-year testing volumes by 28 percent to 167,172.

The companies will use Natera's Signatera circulating tumor DNA assay to assess response to NEO-PV-01, a clinical trial-stage neoantigen cancer vaccine.

The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.

The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.

The Signatera research-use-only assay monitors cancer treatment and assesses minimal residual disease, and is customized for individual patients.

The firm is working on harnessing its ability to assess fetal fraction to develop new methods to predict fetal aneuploidy risks and pregnancy complications.

The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.

Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.